About Vybion

Since 1995 Vybion innovations have met significant needs in the recombinant protein development market. Milestones include:

• Developed more than 100 recombinant proteins for therapeutic and diagnostic applications
• ProCode^TM Technologies, a proprietary proteomics platform

Ongoing research at Vybion brings continually advancing capabilities to our clients.

• Collaboration with Cornell University provides a wide range of capabilities
• NIH-funded research to enhance gene expression through transcriptional enhancement

Contract Biopharmaceutical Development

Contract biopharmaceutical development is an important strategic thrust of our business.

• Optimized genes cloned and expressed in several systems
• Early stage bioprocess development
• Fermentation, process optimization, and scale up through clinical manufacturing
• Clients include major pharmaceutical companies, virtual and startup companies
• Development of CoFab for acute care